Related Experiment Videos
Current developments in HIV chemotherapy.
D Christopher Meadows1, Jacquelyn Gervay-Hague
1Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA.
Chemmedchem
|August 8, 2006
Summary
New HIV treatments are crucial due to rising cases and drug resistance. This review highlights current and novel inhibitors, focusing on HIV integrase, to combat the global epidemic.
Area of Science:
- Virology
- Infectious Diseases
- Pharmacology
Background:
- HIV infection remains a leading global cause of death, with 2004 seeing record new diagnoses.
- Highly Active Antiretroviral Therapy (HAART) uses multiple drug classes but faces challenges.
- Toxicity, patient adherence, and the emergence of drug-resistant HIV necessitate novel therapeutic strategies.
Purpose of the Study:
- To review current clinical candidates for HIV treatment.
- To present novel compounds targeting new viral mechanisms.
- To emphasize the development of HIV integrase inhibitors.
Main Methods:
- Review of existing literature on HIV therapeutics.
- Analysis of clinical candidates across different inhibitor classes.
- Focus on emerging drug targets, particularly HIV integrase.
Main Results:
- Presentation of established inhibitor classes.
- Identification of lead compounds for new therapeutic targets.
- Detailed examination of HIV integrase inhibitors as a promising avenue.
Conclusions:
- Continued development of antiretroviral therapies is essential.
- Novel drug targets and inhibitors, such as those for HIV integrase, are critical for overcoming resistance.
- Advancing HIV treatment requires a multi-pronged approach including new drug classes and improved adherence strategies.